HeyJaredMichael Erman
- Indexed articles, last 90 days
- 4
- Latest publication
- Aug 13, 2026
- Outlet visibility, for yahoo.com
- Top 1K sites
- Earliest in this view
- Jul 15, 2026
Latest articles
Novo CEO says obesity market won't be winner-take-all battle with Lilly (opens the original)
Read excerpt
NEW YORK, Aug 13 (Reuters) - Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will keep it from becoming a winner-take-all battle with rival Eli Lilly. Novo was first to bring a highly effective GLP-1 weight-loss injection, Wegovy, to the U.S. market, but is under pressure to regain ground lost to Lilly's Zepbound in a business that analysts expect will be worth more than $100 billio
Merck posts better-than-expected second-quarter results on Keytruda strength (opens the original)
Read excerpt
Aug 4 (Reuters) - Merck reported higher-than-expected second-quarter sales on Tuesday and raised its full-year revenue forecast on the strength of its top-selling cancer treatment Keytruda. The U.S. drugmaker reported quarterly revenue of $16.61 billion, up 5% from a year earlier and above analysts' average estimate of $16.36 billion, according to LSEG data. Merck reported a loss for the quarter due to a $5.7 billion charge from its acquisition of cancer drug developer Terns Pharmaceuticals. T
Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results (opens the original)
Read excerpt
July 30 (Reuters) - Bristol Myers Squibb raised its full-year revenue and profit forecast on Thursday after reporting second-quarter results that came in well ahead of Wall Street estimates, driven by strong sales of blood thinner Eliquis and newer drugs like heart medicine Camzyos and anemia treatment Reblozyl. The U.S. drugmaker reported second-quarter revenue of $12.97 billion, up 6% from a year earlier and above analysts' average estimate of $11.75 billion, according to LSEG data. Adjuste
J&J quarterly earnings beat Wall Street estimates on strength of medicines unit (opens the original)
Read excerpt
July 15 (Reuters) - Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster Darzalex more than offset erosion from older products and a drop in sales for heart pumps it picked up in its 2022 acquisition of Abiomed. J&J also increased its full-year sales and profit forecast. The healthcare conglomerate reported second-quarter sales of $25.31 billion, up 6.6% from a year earlier and above
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1K sites
For yahoo.com, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.